• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

估算慢性肾脏病患者继发性甲状旁腺功能亢进症的全球患病率。

Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease.

机构信息

Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

出版信息

Front Endocrinol (Lausanne). 2024 Jun 21;15:1400891. doi: 10.3389/fendo.2024.1400891. eCollection 2024.

DOI:10.3389/fendo.2024.1400891
PMID:38974573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11224516/
Abstract

BACKGROUND

Chronic kidney disease (CKD)-related secondary hyperparathyroidism (SHPT) is associated with higher morbidity and death. The goal of this study was to mine the SHPT data already available to do a meta-analysis on the global prevalence of SHPT caused by CKD.

METHODS

Embase, Medline, Web of Science, Cochrane Central Databases, and Google Scholar were searched to identify studies on the prevalence of SHPT due to CKD from inception to November 2023. Pooled prevalence was calculated using the DerSimonian-Laird random effects model with a logit transformation.

RESULTS

Twenty-one eligible studies involving 110977 patients were included. Our results revealed that the estimated global prevalence of SHPT due to CKD was 49.5% (95% CI 30.20-68.18), regardless of the diagnostic criteria. For subgroup analysis, Southern Asia (84.36%, 95% CI 79.35-88.34) had a significantly higher SHPT prevalence than other geographic regions. SHPT due to CKD was most prevalent in China (85.14%, 95% CI 81.74-88.00).

CONCLUSIONS

SHPT due to CKD is highly prevalent. This necessitates awareness and therapeutic approaches from primary care physicians, medical professionals, and health strategy authorities.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/PROSPERO, identifier CRD42024514007.

摘要

背景

慢性肾脏病(CKD)相关的继发性甲状旁腺功能亢进症(SHPT)与更高的发病率和死亡率相关。本研究的目的是挖掘已经可用的 SHPT 数据,对 CKD 引起的 SHPT 的全球患病率进行荟萃分析。

方法

从建库至 2023 年 11 月,我们在 Embase、Medline、Web of Science、Cochrane 中央数据库和 Google Scholar 上搜索了关于 CKD 引起的 SHPT 患病率的研究。使用德西曼-莱尔德随机效应模型和对数转换计算汇总患病率。

结果

共纳入 21 项符合条件的研究,涉及 110977 例患者。我们的结果显示,CKD 引起的 SHPT 的全球估计患病率为 49.5%(95%CI 30.20-68.18),无论采用何种诊断标准。对于亚组分析,南亚(84.36%,95%CI 79.35-88.34)的 SHPT 患病率明显高于其他地理区域。中国(85.14%,95%CI 81.74-88.00)CKD 引起的 SHPT 患病率最高。

结论

CKD 引起的 SHPT 患病率很高。这需要初级保健医生、医疗专业人员和卫生策略当局提高认识并采取治疗措施。

系统评价注册

https://www.crd.york.ac.uk/PROSPERO,标识符 CRD42024514007。

相似文献

1
Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease.估算慢性肾脏病患者继发性甲状旁腺功能亢进症的全球患病率。
Front Endocrinol (Lausanne). 2024 Jun 21;15:1400891. doi: 10.3389/fendo.2024.1400891. eCollection 2024.
2
Secondary hyperparathyroidism among Nigerians with chronic kidney disease.尼日利亚慢性肾脏病患者中的继发性甲状旁腺功能亢进
Afr Health Sci. 2018 Jun;18(2):446-457. doi: 10.4314/ahs.v18i2.30.
3
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.慢性肾脏病继发性甲状旁腺功能亢进的治疗结果及直接治疗成本
J Manag Care Pharm. 2007 Jun;13(5):397-411. doi: 10.18553/jmcp.2007.13.5.397.
4
Metabolomic profile of secondary hyperparathyroidism in patients with chronic kidney disease stages 3-5 not receiving dialysis.未接受透析的慢性肾脏病 3-5 期患者继发甲状旁腺功能亢进的代谢组学特征。
Front Endocrinol (Lausanne). 2024 Jul 4;15:1406690. doi: 10.3389/fendo.2024.1406690. eCollection 2024.
5
Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels.Pin1与慢性肾脏病继发性甲状旁腺功能亢进:基因多态性与蛋白水平
Ren Fail. 2017 Nov;39(1):159-165. doi: 10.1080/0886022X.2016.1256310. Epub 2016 Nov 23.
6
Economic burden of secondary hyperparathyroidism in Germany: a matched comparison.德国继发性甲状旁腺功能亢进症的经济负担:一项匹配比较。
Int Urol Nephrol. 2023 May;55(5):1291-1300. doi: 10.1007/s11255-022-03425-9. Epub 2022 Dec 8.
7
Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.继发性甲状旁腺功能亢进和高磷血症对慢性肾脏病进展及心血管事件的独立影响:来自NEFRONA队列的分析
Nephrol Dial Transplant. 2022 Mar 25;37(4):663-672. doi: 10.1093/ndt/gfab184.
8
Real-World Analysis of Outcomes and Economic Burden in Patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a Sample of the Italian Population.意大利人群样本中慢性肾脏病伴和不伴继发性甲状旁腺功能亢进症患者的结局和经济负担的真实世界分析。
Nutrients. 2023 Jan 10;15(2):336. doi: 10.3390/nu15020336.
9
Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.继发性甲状旁腺功能亢进的慢性肾脏病患者甲状旁腺切除术后的长期死亡率:一项系统评价和荟萃分析。
Ren Fail. 2016 Aug;38(7):1050-8. doi: 10.1080/0886022X.2016.1184924. Epub 2016 May 19.
10
Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.针对 3 至 4 期慢性肾脏病及维生素 D 缺乏症患者继发性甲状旁腺功能亢进症的当前治疗选择。
Expert Opin Drug Saf. 2021 Nov;20(11):1333-1349. doi: 10.1080/14740338.2021.1931117. Epub 2021 Jun 9.

引用本文的文献

1
Intraoperative parathyroid hormone monitoring to guide surgery in renal hyperparathyroidism (PEREGRINE): a protocol for a randomised multiarm surgical pilot trial.术中甲状旁腺激素监测指导肾性甲状旁腺功能亢进手术(PEREGRINE):一项随机多臂手术试点试验方案
BMJ Open. 2025 Jul 17;15(7):e098860. doi: 10.1136/bmjopen-2025-098860.
2
Whole Exome Sequencing in 26 Saudi Patients Expands the Mutational and Clinical Spectrum of Diabetic Nephropathy.对26名沙特患者进行的全外显子组测序扩展了糖尿病肾病的突变和临床谱。
Medicina (Kaunas). 2025 May 29;61(6):1017. doi: 10.3390/medicina61061017.
3
Correlation between parathyroid volume and calcium and phosphorus metabolism in maintenance hemodialysis patients based on Doppler ultrasound technology.

本文引用的文献

1
Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease.慢性肾脏病成人患者的继发性甲状旁腺功能亢进与不良健康结局
Clin Kidney J. 2021 Jan 20;14(10):2213-2220. doi: 10.1093/ckj/sfab006. eCollection 2021 Oct.
2
Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients.肾移植受者甲状旁腺功能亢进症的患病率及危险因素。
Surgery. 2022 Jan;171(1):69-76. doi: 10.1016/j.surg.2021.03.067. Epub 2021 Jul 12.
3
Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.
基于多普勒超声技术的维持性血液透析患者甲状旁腺体积与钙磷代谢的相关性
Int Urol Nephrol. 2025 May 15. doi: 10.1007/s11255-025-04561-8.
4
Efficacy and safety of intermittent intravenous doxercalciferol in the treatment of secondary hyperparathyroidism in Chinese patients on maintenance hemodialysis: a phase II, open-label, prospective, multicenter study.间歇性静脉注射多西骨化醇治疗维持性血液透析中国患者继发性甲状旁腺功能亢进的疗效与安全性:一项II期、开放标签、前瞻性、多中心研究
Front Pharmacol. 2025 Apr 11;16:1574679. doi: 10.3389/fphar.2025.1574679. eCollection 2025.
慢性肾脏病中的心血管疾病:病理生理学见解与治疗选择。
Circulation. 2021 Mar 16;143(11):1157-1172. doi: 10.1161/CIRCULATIONAHA.120.050686. Epub 2021 Mar 15.
4
Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review.慢性肾脏病的负担按 KDIGO 肾小球滤过率和蛋白尿类别分类:系统评价。
Adv Ther. 2021 Jan;38(1):180-200. doi: 10.1007/s12325-020-01568-8. Epub 2020 Nov 24.
5
Prevalence and pattern of chronic kidney disease-mineral bone disorders among hemodialysis patients in kano, northwest nigeria.尼日利亚西北部卡诺地区血液透析患者慢性肾脏病-矿物质和骨异常的患病率及模式
Ann Afr Med. 2019 Oct-Dec;18(4):191-195. doi: 10.4103/aam.aam_18_19.
6
Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.慢性肾脏病与冠状动脉疾病:美国心脏病学会心血管介入治疗学会最新进展综述。
J Am Coll Cardiol. 2019 Oct 8;74(14):1823-1838. doi: 10.1016/j.jacc.2019.08.1017.
7
THE PREVALENCE OF BIOCHEMICAL ABNORMALITIES OF CHRONIC KIDNEY DISEASE. MINERAL AND BONE DISORDERS IN UNTREATED NON-DIALYSIS PATIENTS - A MULTICENTER STUDY.慢性肾脏病矿物质和骨异常在未经治疗的非透析患者中的患病率——一项多中心研究
Acta Endocrinol (Buchar). 2016 Jul-Sep;12(3):282-290. doi: 10.4183/aeb.2016.282.
8
Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET).2015 年中国肾脏病网络(CK-NET)年度数据报告执行摘要。
Kidney Int. 2019 Mar;95(3):501-505. doi: 10.1016/j.kint.2018.11.011.
9
Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis.用于复发性1型丙型肝炎病毒感染的肝移植受者的直接抗病毒药物:系统评价和荟萃分析。
Transpl Infect Dis. 2019 Apr;21(2):e13047. doi: 10.1111/tid.13047. Epub 2019 Jan 21.
10
Secondary hyperparathyroidism among Nigerians with chronic kidney disease.尼日利亚慢性肾脏病患者中的继发性甲状旁腺功能亢进
Afr Health Sci. 2018 Jun;18(2):446-457. doi: 10.4314/ahs.v18i2.30.